Today, $Meso’s cell therapy remestemcel-L was recognized as a 2020 winner of the Fierce Innovation Awards: Life Sciences Edition. The Biotech Innovation category showcases forward thinking products that have the greatest opportunity to impact the industry bit.ly/33tbiDD

Randomized Controlled Phase 3 Trial of Remestemcel-L for Reduced Mortality in COVID-19 Acute Respiratory Distress Syndrome Surpasses 50% Enrollment bit.ly/2Ir18g7

Randomized Controlled Study Using Direct Injection of Remestemcel-L Into Inflamed Gut of Patients With Crohn’s Disease and Ulcerative Colitis bit.ly/3dM2IEK

Update on Remestemcel-L For the Treatment of COVID-19 ARDS and Steroid-Refractory Acute GVHD bit.ly/37Nu909

$Meso’s collaborative RCT with Cleveland Clinic will test for the first time direct delivery of remestemcel-L to the inflamed gut tissue in up to 48 patients with #CrohnsDisease and ulcerative colitis. bit.ly/3mAbPf7

$MESO Vice Chairman, William A. Burns, has served on the Board of Directors since 2014. He is a member of the Oncology Advisory Board of the Universities of Cologne/Bonn in Germany, a trustee of the Institute of Cancer Research and a Governor of The Wellcome Trust.

$MESO & #ClevelandClinic are collaborating on a RCT delivering remestemcel-L by an endoscope directly to the inflamed gut of patients with medically refractory Crohn’s disease and ulcerative colitis. In the US, 3M suffer from these debilitating conditions. bit.ly/3mAbPf7

Second Interim Analysis of Clinical Outcomes After 135 Patients Results in Recommendation to Continue Remestemcel-L Phase 3 Trial in COVID-19 ARDS bit.ly/36iGPti

Independent Data Safety Monitoring Board recommends continuation of $MESO’s Phase 3 trial following second interim analysis reviewing primary endpoint of remestemcel-L in 135 patients with #COVID19 ARDS, the primary cause of death from COVID-19. bit.ly/2Ud0AwL

Mesoblast Corporate Update and Financial Results Webcast bit.ly/3kQG8Nc

Mesoblast Enters Global Collaboration for Development, Manufacture and Commercialization of Remestemcel-L bit.ly/2ISNNgX

Operational and Financial Results for the Period Ended September 30, 2020 bit.ly/2IVeLVf

FDA Grants Fast Track Designation for Remestemcel-L in the Treatment of Acute Respiratory Distress Syndrome Due to COVID-19 bit.ly/3g5eQSv

Remestemcel-L Reduces Inflammatory Biomarkers Predictive of High Mortality in Acute Graft Versus Host Disease bit.ly/3ovwdip

Mesoblast Provides Topline Results From Phase 3 Trial of Rexlemestrocel-L for Advanced Chronic Heart Failure bit.ly/3mnVklz

Mesoblast Presents Heart Failure Phase 3 Trial Results at Investor Healthcare Conference bit.ly/3qhmo8N

Mesoblast Operational and Financial Highlights for Quarter Ended December 31, 2020 bit.ly/2YpiQFC

Mesoblast Phase 3 Trial Shows That a Single Injection of Rexlemestrocel-L + Hyaluronic Acid Carrier Results in at Least Two Years of Pain Reduction With Opioid Sparing Activity in Patients With Chronic Low Back Pain Due to Degenerative Disc Disease bit.ly/3aSkBAH

Positive Outcomes of First Children Treated With Remestemcel-L for Multisystem Inflammatory Syndrome (MIS-C) and Heart Failure Post-COVID-19 Published in Pediatrics bit.ly/3pqi3Pz

Mesoblast Operational Highlights and Upcoming Milestones bit.ly/3m9CosC